Literature DB >> 17584038

Development of ribozyme-based gene-inactivations; the example of the hepatitis delta virus ribozyme.

M Asif-Ullah1, Michel Lévesque, Gilles Robichaud, Jean-Pierre Perreault.   

Abstract

The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozyme-based gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584038     DOI: 10.2174/156652307780859008

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  11 in total

1.  A triplex ribozyme expression system based on a single hairpin ribozyme.

Authors:  Guillermo Aquino-Jarquin; María Luisa Benítez-Hess; Joseph A DiPaolo; Luis M Alvarez-Salas
Journal:  Oligonucleotides       Date:  2008-09

2.  Investigating a new generation of ribozymes in order to target HCV.

Authors:  Michel V Lévesque; Dominique Lévesque; Francis P Brière; Jean-Pierre Perreault
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

3.  Development of an isoform-specific gene suppression system: the study of the human Pax-5B transcriptional element.

Authors:  Gilles A Robichaud; Jean-Pierre Perreault; Rodney J Ouellette
Journal:  Nucleic Acids Res       Date:  2008-07-10       Impact factor: 16.971

Review 4.  Prospects for nucleic acid-based therapeutics against hepatitis C virus.

Authors:  Chang Ho Lee; Ji Hyun Kim; Seong-Wook Lee
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

5.  Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting.

Authors:  Michel V Lévesque; Samuel G Rouleau; Jean-Pierre Perreault
Journal:  Nucleic Acid Ther       Date:  2011-07-08       Impact factor: 5.486

6.  Correlation between hammerhead ribozyme-mediated eggshell protein gene cleavage and reproduction inhibition of Schistosoma japonicum.

Authors:  Yu Liang; Yuelan Zhou; Weiguo Yin; Yingju Li; Qiulin Yang; Yuan Gao; Yukuai Zhang; Yaofei Yang; Li Peng; Jianhua Xiao
Journal:  Mol Med Rep       Date:  2012-01-12       Impact factor: 2.952

7.  Silencing of amyloid precursor protein expression using a new engineered delta ribozyme.

Authors:  Manel Ben Aissa; Marie-Claude April; Lucien-Junior Bergeron; Jean-Pierre Perreault; Georges Levesque
Journal:  Int J Alzheimers Dis       Date:  2012-02-12

8.  A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease.

Authors:  Julie Motard; Ronan Rouxel; Alexandra Paun; Veronika von Messling; Martin Bisaillon; Jean-Pierre Perreault
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

9.  Controlling mammalian gene expression by allosteric hepatitis delta virus ribozymes.

Authors:  Yoko Nomura; Linlin Zhou; Anh Miu; Yohei Yokobayashi
Journal:  ACS Synth Biol       Date:  2013-05-22       Impact factor: 5.110

10.  A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.

Authors:  Robert J Scarborough; Michel V Lévesque; Etienne Boudrias-Dalle; Ian C Chute; Sylvanne M Daniels; Rodney J Ouellette; Jean-Pierre Perreault; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2014-07-29       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.